Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 15/20 | 0.52 |
| ▸ | PIM3 | Q86V86 | 15/20 | 0.52 |
| ▸ | PIM2 | Q9P1W9 | 15/20 | 0.52 |
| ▸ | CKS1B | P61024 | 2/20 | 0.47 |
| ▸ | SKP1 | P63208 | 2/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.44 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15400922 | 0.91 | PIM1 (0.64) | PIM1PIM3PIM2CKS1BSKP1 | |
| SCHEMBL15401156 | 0.88 | PIM1 (0.56) | PIM1PIM3PIM2LRRK2MAP4K1 | |
| SCHEMBL15401100 | 0.86 | PIM1 (0.64) | PIM1PIM3PIM2CKS1BSKP1 | |
| SCHEMBL15400672 | 0.84 | CKS1B (0.50) | PIM1PIM3PIM2CKS1BSKP1 | |
| SCHEMBL15400274 | 0.83 | PIM1 (0.66) | PIM1PIM3PIM2 | |
| SCHEMBL15401371 | 0.82 | PIM1 (0.49) | PIM1PIM3PIM2CKS1BSKP1 | |
| SCHEMBL15401846 | 0.81 | PIM1 (0.61) | PIM1PIM3PIM2CKS1BSKP1 | |
| SCHEMBL20459966 | 0.81 | PIM1 (0.58) | PIM1PIM3PIM2LRRK2 | |
| SCHEMBL15402052 | 0.80 | PIM1 (0.55) | PIM1PIM3PIM2MAP4K1 | |
| SCHEMBL15401687 | 0.79 | PIM1 (0.55) | PIM1PIM3PIM2MAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2867232-B1 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2018-08-08 | — | — | EP | disclosed |
| EP-2867232-B1 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2018-08-08 | — | — | EP | disclosed |
| US-9434725-B2 | 5-azaindazole compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-06 | — | — | US | disclosed |
| US-9434725-B2 | 5-azaindazole compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-06 | — | — | US | disclosed |
| US-9434725-B2 | 5-azaindazole compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-06 | — | — | US | disclosed |
| US-20140005168-A1 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | GENENTECH,INC. | 2014-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005168-A1 | 5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE | PIM1, PIM3, PIM2 | PIM1 1/4885PIM3 2/4885PIM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.